ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report

RATIONALE: The anaplastic lymphoma kinase (ALK) rearrangements represent a subtype of nonsmall-cell lung cancer (NSCLC), and targeting ALK has radically changed the treatment of NSCLC. Crizotinib, as an ALK inhibitor, has been used in the treatment of ALK-rearranged NSCLC for several years and some...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Ye, Li, Bixun, Zhang, Yihong, Guo, Xiaoyun, Xiang, Chunzhi, Wang, Congshui, Lu, Yang, Ren, Shuang, Zhao, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426651/
https://www.ncbi.nlm.nih.gov/pubmed/30882666
http://dx.doi.org/10.1097/MD.0000000000014826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426651/
https://www.ncbi.nlm.nih.gov/pubmed/30882666
http://dx.doi.org/10.1097/MD.0000000000014826

Ejemplares similares